Ruth Ann Marrie

Ruth Ann Marrie's AcademicInfluence.com Rankings

Ruth Ann Marrie

Medical

#2339

World Rank

#2758

Historical Rank

Neurology

#222

World Rank

#298

Historical Rank

Epidemiology

#413

World Rank

#432

Historical Rank

medical Degrees

Ruth Ann Marrie

Philosophy

#6800

World Rank

#9903

Historical Rank

Logic

#3905

World Rank

#5132

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Ruth Ann Marrie's Degrees

Masters Epidemiology University of Manitoba
PhD Epidemiology University of Manitoba

Why Is Ruth Ann Marrie Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Ruth Ann Marrie's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria (2017) (3544)
Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition (2020) (531)
Evaluation of the six-minute walk in multiple sclerosis subjects and healthy controls (2008) (524)
The prevalence of MS in the United States (2019) (494)
Incidence and prevalence of multiple sclerosis in Europe: a systematic review (2013) (438)
Environmental risk factors in multiple sclerosis aetiology (2004) (376)
The incidence and prevalence of psychiatric disorders in multiple sclerosis: A systematic review (2015) (370)
Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study (2011) (288)
A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: Overview (2015) (265)
Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis (2004) (263)
Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis (2018) (235)
Validity of performance scales for disability assessment in multiple sclerosis (2007) (231)
Quantile regression and restricted cubic splines are useful for exploring relationships between continuous variables. (2009) (224)
Incidence and Prevalence of Multiple Sclerosis in the Americas: A Systematic Review (2013) (199)
A comparative study of the gut microbiota in immune-mediated inflammatory diseases—does a common dysbiosis exist? (2018) (190)
The rising prevalence and changing age distribution of multiple sclerosis in Manitoba (2010) (178)
Emerging effects of comorbidities on multiple sclerosis (2010) (171)
Resting state sensorimotor functional connectivity in multiple sclerosis inversely correlates with transcallosal motor pathway transverse diffusivity (2008) (170)
MRI parameters for prediction of multiple sclerosis diagnosis in children with acute CNS demyelination: a prospective national cohort study (2011) (162)
Effect of comorbidity on mortality in multiple sclerosis (2015) (158)
Does multiple sclerosis–associated disability differ between races? (2006) (148)
Comorbidity in multiple sclerosis: implications for patient care (2017) (137)
Serial Anti–Myelin Oligodendrocyte Glycoprotein Antibody Analyses and Outcomes in Children With Demyelinating Syndromes (2019) (137)
Mental comorbidity and multiple sclerosis: validating administrative data to support population-based surveillance (2013) (135)
Increased Burden of Psychiatric Disorders in Inflammatory Bowel Disease. (2018) (134)
2010 McDonald criteria for diagnosing pediatric multiple sclerosis (2012) (130)
Systematic review and meta-analysis of interventions for depression and anxiety in persons with multiple sclerosis. (2016) (127)
A systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple sclerosis (2015) (127)
A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis (2015) (126)
Preferred Sources of Health Information in Persons With Multiple Sclerosis: Degree of Trust and Information Sought (2013) (125)
Validation of a Self-Report Comorbidity Questionnaire for Multiple Sclerosis (2010) (121)
High incidence and increasing prevalence of multiple sclerosis in British Columbia, Canada: findings from over two decades (1991–2010) (2015) (118)
Rising prevalence of vascular comorbidities in multiple sclerosis: validation of administrative definitions for diabetes, hypertension, and hyperlipidemia (2012) (116)
Increased incidence of psychiatric disorders in immune-mediated inflammatory disease. (2017) (112)
Association of fatigue and brain atrophy in multiple sclerosis (2005) (112)
Psychiatric comorbidity is associated with disability progression in multiple sclerosis (2018) (109)
Diet quality is associated with disability and symptom severity in multiple sclerosis (2018) (108)
A systematic review of the incidence and prevalence of sleep disorders and seizure disorders in multiple sclerosis (2015) (107)
Health-related quality of life in multiple sclerosis (2016) (102)
Differences in the burden of psychiatric comorbidity in MS vs the general population (2015) (101)
Under treatment of overactive bladder symptoms in patients with multiple sclerosis: an ancillary analysis of the NARCOMS Patient Registry. (2010) (100)
Health-care use before a first demyelinating event suggestive of a multiple sclerosis prodrome: a matched cohort study (2017) (99)
Depression in multiple sclerosis (2017) (98)
The impact of sexual dysfunction on health-related quality of life in people with multiple sclerosis (2014) (93)
The validity and reliability of screening measures for depression and anxiety disorders in multiple sclerosis. (2018) (92)
General Health Issues in Multiple Sclerosis: Comorbidities, Secondary Conditions, and Health Behaviors (2013) (92)
Patient Health Questionnaire-9 scores do not accurately estimate depression prevalence: individual participant data meta-analysis. (2020) (91)
The Prevalence of Multiple Sclerosis in 3 US Communities (2009) (86)
Predictors of alternative medicine use by multiple sclerosis patients (2003) (85)
Subjective cognitive complaints relate to mild impairment of cognition in multiple sclerosis (2005) (84)
Sex differences in comorbidity at diagnosis of multiple sclerosis (2016) (83)
Comorbidity increases the risk of hospitalizations in multiple sclerosis (2015) (82)
Dramatically changing rates and reasons for hospitalization in multiple sclerosis (2014) (82)
Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders (2019) (81)
Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis (2016) (81)
Changes in the ascertainment of multiple sclerosis (2005) (80)
Increased Burden of Psychiatric Disorders in Rheumatoid Arthritis (2018) (78)
A systematic review of the incidence and prevalence of cancer in multiple sclerosis (2015) (77)
Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study (2018) (76)
Infection-related health care utilization among people with and without multiple sclerosis (2017) (74)
The Utility of Administrative Data for Surveillance of Comorbidity in Multiple Sclerosis: A Validation Study (2012) (74)
Rising incidence of psychiatric disorders before diagnosis of immune-mediated inflammatory disease (2017) (74)
Disparities in the management of multiple sclerosis–related bladder symptoms (2007) (73)
Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis (2018) (69)
Comorbidity increases the risk of relapse in multiple sclerosis (2017) (68)
The Multiple Sclerosis Intimacy and Sexuality Questionnaire — re-validation and development of a 15-item version with a large US sample (2013) (68)
The Validity and Reliability of Screening Measures for Depression and Anxiety Disorders in Inflammatory Bowel Disease. (2018) (66)
Diagnostic data for neurological conditions in interRAI assessments in home care, nursing home and mental health care settings: a validity study (2013) (66)
Systematic Review and Meta-analysis of Interventions for Depression and Anxiety in Persons With Rheumatoid Arthritis (2017) (66)
MRI and laboratory features and the performance of international criteria in the diagnosis of multiple sclerosis in children and adolescents: a prospective cohort study. (2018) (66)
Validation of the NARCOMS Registry: fatigue assessment (2005) (65)
Multiple sclerosis and Epstein-Barr virus. (2002) (64)
Comorbid anxiety, depression, and cognition in MS and other immune-mediated disorders (2019) (63)
Multiple sclerosis in Canada 2011 to 2031: results of a microsimulation modelling study of epidemiological and economic impacts. (2017) (63)
Recommendations for observational studies of comorbidity in multiple sclerosis (2016) (62)
Validity and reliability of the MSQ LI in cognitively impaired patients with multiple sclerosis (2003) (60)
Functional pathway-defined MRI diffusion measures reveal increased transverse diffusivity of water in multiple sclerosis (2006) (60)
The Incidence and Prevalence of Multiple Sclerosis in Nova Scotia, Canada (2013) (59)
Effects of physical comorbidities on disability progression in multiple sclerosis (2018) (59)
Can T1w/T2w ratio be used as a myelin‐specific measure in subcortical structures? Comparisons between FSE‐based T1w/T2w ratios, GRASE‐based T1w/T2w ratios and multi‐echo GRASE‐based myelin water fractions (2018) (58)
Psychiatric comorbidity increases mortality in immune-mediated inflammatory diseases. (2018) (56)
The incidence and prevalence of neuromyelitis optica: a systematic review. (2013) (56)
Temporal trends in multiple sclerosis prevalence and incidence in a large population (2018) (54)
Adherence and persistence to drug therapies for multiple sclerosis: A population-based study. (2016) (54)
The Prevalence and Risk Factors of Undiagnosed Depression and Anxiety Disorders Among Patients With Inflammatory Bowel Disease. (2019) (53)
The Prevalence and Risk Factors of Undiagnosed Depression and Anxiety Disorders Among Patients With Inflammatory Bowel Disease. (2019) (53)
An Intervention to Improve Procedure Education for Internal Medicine Residents (2008) (52)
Multiple sclerosis and varicella zoster virus infection: A review (2001) (50)
Five years before multiple sclerosis onset: Phenotyping the prodrome (2018) (50)
Multiple sclerosis and antecedent infections: A case‐control study (2000) (48)
Drug Insight: interferon treatment in multiple sclerosis (2006) (48)
Establishing the Incidence and Prevalence of Multiple Sclerosis in Saskatchewan (2018) (47)
Abnormal effector and regulatory T cell subsets in paediatric-onset multiple sclerosis (2019) (47)
Validation of an algorithm for identifying MS cases in administrative health claims datasets (2019) (47)
A cross-sectional study of bone health in multiple sclerosis (2009) (46)
Employment and absenteeism in working-age persons with multiple sclerosis (2017) (46)
High rates of physician services utilization at least five years before multiple sclerosis diagnosis (2013) (46)
Clinical features of dog- and bat-acquired rabies in humans. (2013) (45)
The association of fatigue, pain, depression and anxiety with work and activity impairment in immune mediated inflammatory diseases (2018) (45)
Performance of administrative case definitions for depression and anxiety in inflammatory bowel disease. (2016) (45)
Leveraging real-world data to investigate multiple sclerosis disease behavior, prognosis, and treatment (2019) (45)
Validity and Reliability of Screening Measures for Depression and Anxiety Disorders in Rheumatoid Arthritis (2020) (44)
Five-minute Apgar score as a marker for developmental vulnerability at 5 years of age (2015) (44)
International consensus on quality standards for brain health-focused care in multiple sclerosis (2018) (44)
Determinants of non-adherence to disease-modifying therapies in multiple sclerosis: A cross-Canada prospective study (2016) (44)
The incidence and prevalence of comorbid gastrointestinal, musculoskeletal, ocular, pulmonary, and renal disorders in multiple sclerosis: A systematic review (2015) (44)
Puberty in females enhances the risk of an outcome of multiple sclerosis in children and the development of central nervous system autoimmunity in mice (2015) (44)
Impact of multiple sclerosis relapse: The NARCOMS participant perspective. (2015) (43)
Viral exposures and MS outcome in a prospective cohort of children with acquired demyelination (2016) (42)
Evaluating the Risk of Macrovascular Events and Mortality Among People With Multiple Sclerosis in England. (2020) (42)
The Canadian survey of health, lifestyle and ageing with multiple sclerosis: methodology and initial results (2014) (41)
A Cross-Sectional Study of the Impact of Spasticity on Daily Activities in Multiple Sclerosis (2016) (41)
The Incidence and Prevalence of Thyroid Disease Do Not Differ in the Multiple Sclerosis and General Populations: A Validation Study Using Administrative Data (2012) (41)
The challenge of comorbidity in clinical trials for multiple sclerosis (2016) (41)
Recovery From Central Nervous System Acute Demyelination in Children (2015) (40)
A survey of dietary characteristics in a large population of people with multiple sclerosis. (2018) (40)
Epstein-Barr virus in oral shedding of children with multiple sclerosis (2013) (40)
Use of eHealth and mHealth technology by persons with multiple sclerosis. (2019) (40)
The 2013 clinical course descriptors for multiple sclerosis (2020) (39)
Comorbidity is associated with pain-related activity limitations in multiple sclerosis. (2015) (38)
Health Literacy Association With Health Behaviors and Health Care Utilization in Multiple Sclerosis: A Cross-Sectional Study (2014) (38)
Validation of the NARCOMS Registry: pain assessment (2005) (38)
Prevalence and incidence of ischemic heart disease in multiple sclerosis: A population-based validation study. (2013) (37)
Multiple sclerosis and antecedent infections (2000) (37)
Substantial adverse association of visual and vascular comorbidities on visual disability in multiple sclerosis (2011) (37)
Systematic review of interventions for depression and anxiety in persons with inflammatory bowel disease (2016) (37)
Monophasic demyelination reduces brain growth in children (2017) (35)
Estimating annual prevalence of depression and anxiety disorder in multiple sclerosis using administrative data (2017) (35)
Parent-of-origin effect in multiple sclerosis (2009) (35)
A surface‐in gradient of thalamic damage evolves in pediatric multiple sclerosis (2019) (35)
The multiple sclerosis prodrome: Emerging evidence, challenges, and opportunities (2020) (35)
Common variation near IRF6 is associated with IFN-β-induced liver injury in multiple sclerosis (2018) (34)
Fatigue and Comorbidities in Multiple Sclerosis. (2016) (34)
The multiple sclerosis relapse experience: patient-reported outcomes from the North American Research Committee on Multiple Sclerosis (NARCOMS) Registry (2013) (34)
The prevalence of urinary catheterization in women and men with multiple sclerosis (2013) (33)
The Relationship Between Symptoms of Depression and Anxiety and Disease Activity in IBD Over Time. (2021) (33)
Heavy metals, organic solvents, and multiple sclerosis: An exploratory look at gene-environment interactions (2016) (32)
“Seeing” in NARCOMS: a look at vision-related quality of life in the NARCOMS registry (2013) (32)
Diagnoses of Depression and Anxiety Versus Current Symptoms and Quality of Life in Multiple Sclerosis. (2017) (32)
Trigeminal Neuralgia Commonly Precedes the Diagnosis of Multiple Sclerosis. (2017) (32)
Causes of death among persons with multiple sclerosis. (2015) (32)
Diabetes and anxiety adversely affect cognition in multiple sclerosis. (2019) (32)
Clinical and MRI activity as determinants of sample size for pediatric multiple sclerosis trials (2013) (31)
Reliability of Regression-Based Normative Data for the Oral Symbol Digit Modalities Test: An Evaluation of Demographic Influences, Construct Validity, and Impairment Classification Rates in Multiple Sclerosis Samples (2014) (31)
Evaluating the safety of β-interferons in MS (2017) (30)
Smoking Status over Two Years in Patients with Multiple Sclerosis (2008) (29)
Adverse health behaviours are associated with depression and anxiety in multiple sclerosis: A prospective multisite study (2015) (29)
Smokers with Multiple Sclerosis Are More Likely to Report Comorbid Autoimmune Diseases (2011) (29)
Intensive care unit admission in multiple sclerosis (2014) (29)
Functional–structural correlations in the afferent visual pathway in pediatric demyelination (2014) (29)
Adverse psychiatric effects of disease-modifying therapies in multiple Sclerosis: A systematic review. (2018) (28)
MS incidence and prevalence in Africa, Asia, Australia and New Zealand: A systematic review. (2014) (28)
Comorbidity in multiple sclerosis: Past, present and future. (2019) (27)
The incidence and prevalence of fibromyalgia are higher in multiple sclerosis than the general population: A population-based study. (2012) (27)
Increased incidence and prevalence of psoriasis in multiple sclerosis. (2017) (27)
Care Partners and Multiple Sclerosis: Differential Effect on Men and Women. (2015) (26)
Children and adolescents adjustment to parental multiple sclerosis: a systematic review (2014) (26)
A new way to estimate neurologic disease prevalence in the United States (2019) (26)
Substantial burden of dizziness in multiple sclerosis. (2013) (26)
Children of chronically ill parents: Relationship between parental multiple sclerosis and childhood developmental health (2015) (26)
Differing trends in the incidence of vascular comorbidity in MS and the general population (2016) (25)
Perspectives on marijuana use and effectiveness: A survey of NARCOMS participants (2017) (25)
Fatigue, sleep disorders, anaemia and pain in the multiple sclerosis prodrome (2020) (24)
The contribution of secondhand tobacco smoke exposure to pediatric multiple sclerosis risk (2019) (24)
Antidepressant Drug Treatment in Association with Multiple Sclerosis Disease-Modifying Therapy: Using Explorys in the MS Population. (2016) (24)
The Prevalence of Multiple Sclerosis in 3 US Communities: The Role of Vitamin D [Response to Letter] (2010) (24)
Prevalence of neurological conditions across the continuum of care based on interRAI assessments (2014) (24)
A Population-based Study of Intensive Care Unit Admissions in Rheumatoid Arthritis (2016) (24)
Health insurance affects the use of disease-modifying therapy in multiple sclerosis (2016) (23)
Effects of Psychiatric Comorbidity in Immune-Mediated Inflammatory Disease: Protocol for a Prospective Study (2018) (23)
High hypothetical interest in physician-assisted death in multiple sclerosis (2017) (23)
Treatment satisfaction and bothersome bladder, bowel, sexual symptoms in multiple sclerosis. (2018) (22)
The association of fatigue and social participation in multiple sclerosis as assessed using two different instruments. (2019) (22)
Screening Tools for Anxiety in People with Multiple Sclerosis: A Systematic Review. (2016) (22)
Upper limb impairment is associated with use of assistive devices and unemployment in multiple sclerosis. (2017) (22)
A Practical, Global Perspective on Using Administrative Data to Conduct Intensive Care Unit Research. (2015) (22)
Physical comorbidities increase the risk of psychiatric comorbidity in multiple sclerosis (2016) (21)
Masquerades of Acquired Demyelination in Children (2013) (21)
Adherence to disease‐modifying therapies for multiple sclerosis and subsequent hospitalizations (2017) (21)
Multiple sclerosis and antecedent infections: a case-control study. (2000) (21)
Prodrome in relapsing‐remitting and primary progressive multiple sclerosis (2019) (21)
Validation of the NARCOMS Registry: Tremor and Coordination Scale. (2011) (20)
Validation of NARCOMS Depression Scale (2008) (20)
Physical comorbidities increase the risk of psychiatric comorbidity in immune-mediated inflammatory disease. (2018) (20)
Persistence and adherence to the new oral disease-modifying therapies for multiple sclerosis: A population-based study. (2019) (20)
Performance of administrative case definitions for comorbidity in multiple sclerosis in Manitoba and Nova Scotia. (2014) (19)
Traditional risk factors may not explain increased incidence of myocardial infarction in MS (2019) (19)
Comorbidities Are Associated with Altered Health Services Use in Multiple Sclerosis: A Prospective Cohort Study (2018) (19)
Identifying priority outcomes that influence selection of disease-modifying therapies in MS (2018) (19)
Comorbidity is associated with disease activity in MS (2020) (19)
Incidence of Mood or Anxiety Disorders in Children of Parents with Multiple Sclerosis. (2016) (18)
Silent New Brain MRI Lesions in Children with MOG‐Antibody Associated Disease (2020) (18)
Vitamin D in MS (2012) (17)
Peripartum depression in parents with multiple sclerosis and psychiatric disorders in children (2016) (17)
Examining the joint effect of disability, health behaviors, and comorbidity on mortality in MS (2016) (17)
Pediatric-onset multiple sclerosis is associated with reduced parental health–related quality of life and family functioning (2018) (16)
Mining healthcare data for markers of the multiple sclerosis prodrome. (2018) (16)
Patient perspectives on switching disease-modifying therapies in the NARCOMS registry (2014) (16)
Comorbidity in Multiple Sclerosis: Some Answers, More Questions. (2016) (16)
Predictors of Body Image Related Sexual Dysfunction in Men and Women with Multiple Sclerosis (2015) (16)
Impact of parental multiple sclerosis on early childhood development: A retrospective cohort study (2015) (15)
Exploring the implications of small-area variation in the incidence of multiple sclerosis. (2013) (15)
Measures of general and abdominal obesity and disability severity in a large population of people with multiple sclerosis (2020) (15)
Machine-learning models for depression and anxiety in individuals with immune-mediated inflammatory disease. (2020) (15)
Chronic lung disease and multiple sclerosis: Incidence, prevalence, and temporal trends. (2016) (15)
Comorbidity before and after a diagnosis of inflammatory bowel disease (2021) (15)
A systematic review of morbidities suggestive of the multiple sclerosis prodrome. (2020) (15)
Social Determinants of Outcomes in Inflammatory Bowel Disease. (2020) (15)
The computer-based Symbol Digit Modalities Test: establishing age-expected performance in healthy controls and evaluation of pediatric MS patients (2017) (15)
Smokers with MS have greater decrements in quality of life and disability than non-smokers (2017) (15)
The impact of resilience on healthy aging with multiple sclerosis (2020) (14)
Change in the Health-Related Quality of Life of Multiple Sclerosis Patients over 5 Years. (2013) (14)
Accuracy of FRAX® in People With Multiple Sclerosis (2019) (14)
Persistence of use of prescribed cannabinoid medicines in Manitoba, Canada: A population-based cohort study. (2019) (14)
Validation of the PHQ-9 for Suicidal Ideation in Persons with Inflammatory Bowel Disease. (2018) (14)
Increased incidence of critical illness among patients with inflammatory bowel disease: a population-based study. (2014) (14)
Multiple sclerosis is associated with low bone mineral density and osteoporosis. (2019) (14)
Anxiety and Depression Leads to Anti-Tumor Necrosis Factor Discontinuation in Inflammatory Bowel Disease. (2020) (14)
Incidence and prevalence of MS in children (2018) (13)
Persistence to disease-modifying therapies for multiple sclerosis in a Canadian cohort (2017) (13)
Validation of the SymptoMScreen with performance-based or clinician-assessed outcomes. (2019) (13)
Potentially Modifiable Factors Associated With Physical Activity in Individuals With Multiple Sclerosis (2017) (12)
A contemporary profile of primary progressive multiple sclerosis participants from the NARCOMS Registry (2018) (12)
Cerebral arterial and venous blood flow in adolescent multiple sclerosis patients and age‐matched controls using phase contrast MRI (2014) (12)
The gut microbiota in pediatric multiple sclerosis and demyelinating syndromes (2021) (12)
Registry Cohort Study to Determine Risk for Multiple Sclerosis after Vaccination for Pandemic Influenza A(H1N1) with Arepanrix, Manitoba, Canada (2018) (12)
MS risk in immigrants in the McDonald era (2019) (11)
Health care utilization before and after intensive care unit admission in multiple sclerosis. (2015) (11)
Patterns of Attrition in the Canadian Armed Forces Members and Veterans Mental Health Follow-up Survey (CAFVMHS) (2021) (11)
High rates of health care utilization in pediatric multiple sclerosis: A Canadian population-based study (2019) (11)
Application of Three Focused Cluster Detection Methods to Study Geographic Variation in the Incidence of Multiple Sclerosis in Manitoba, Canada (2014) (11)
Factors associated with perceived need for mental health care in multiple sclerosis. (2018) (11)
Autoimmune disease and multiple sclerosis: methods, methods, methods (2007) (11)
Comparison of Spinal Cord Magnetic Resonance Imaging Features Among Children With Acquired Demyelinating Syndromes (2021) (11)
The 2013 Clinical Course Descriptors for Multiple Sclerosis (2020) (10)
Neuregulin-1 beta 1 is implicated in pathogenesis of multiple sclerosis. (2020) (10)
Clinical Profile of Persons with Multiple Sclerosis Across the Continuum of Care (2017) (10)
Spatial normalization of multiple sclerosis brain MRI data depends on analysis method and software package. (2020) (9)
Multiple sclerosis progression: time for a new mechanism-driven framework (2022) (9)
Gender differences in information needs and preferences regarding depression among individuals with multiple sclerosis, inflammatory bowel disease and rheumatoid arthritis. (2019) (9)
Evaluating the safety of &bgr;-interferons in MS: A series of nested case-control studies (2017) (9)
Detection and clinical correlation of leukocortical lesions in pediatric-onset multiple sclerosis on multi-contrast MRI (2018) (9)
When one and one make three (2008) (9)
Prevalence and Risk Factors of Substance Use Disorder in Inflammatory Bowel Disease (2020) (9)
Medical Tourism for CCSVI Procedures in People with Multiple Sclerosis: An Observational Study (2016) (9)
Effect of physical comorbidities on risk of depression in Multiple Sclerosis (2013) (9)
THE INFLUENCE OF COMORBID DISEASES AND HEALTH BEHAVIORS ON CLINICAL CHARACTERISTICS, DISABILITY AT DIAGNOSIS, AND DISABILITY PROGRESSION IN MULTIPLE SCLEROSIS (2007) (8)
2010 McDonald criteria in a pediatric cohort: is positivity at onset associated with a more aggressive multiple sclerosis course? (2013) (8)
Factors associated with receiving bone mineral density screening among people with multiple sclerosis. (2019) (8)
Discriminative ability of quality of life measures in multiple sclerosis (2017) (8)
Medication adherence in multiple sclerosis as a potential model for other chronic diseases: a population-based cohort study (2021) (8)
Demographic, genetic, and environmental factors that modify disease course. (2011) (8)
Management of diabetes and hypertension in people with multiple sclerosis. (2020) (8)
High or increasing serum NfL is predictive of impending multiple sclerosis relapses. (2022) (8)
The 5-Year Incidence of Mental Disorders in a Population-Based ICU Survivor Cohort. (2020) (8)
Examining the Relationship Between Family Caregivers' Emotional States and Ability to Empathize with Patients with Multiple Sclerosis: A Pilot Study. (2016) (8)
Cancer Incidence and Mortality Rates in Multiple Sclerosis (2020) (8)
The 5-year pre- and post-hospitalization treated prevalence of mental disorders and psychotropic medication use in critically ill patients: a Canadian population-based study (2021) (8)
Caught in a no-win situation: discussions about CCSVI between persons with multiple sclerosis and their neurologists – a qualitative study (2017) (7)
Performance of Regression-Based Norms for Cognitive Functioning of Persons With Multiple Sclerosis in an Independent Sample (2021) (7)
Hospitalization is associated with subsequent disability in multiple sclerosis. (2017) (7)
Factors associated with excessive sitting time in multiple sclerosis. (2018) (7)
Impact of comorbidity on hospitalizations in individuals newly diagnosed with multiple sclerosis: A longitudinal population-based study. (2020) (7)
Characteristics of a population-based multiple sclerosis cohort treated with disease-modifying drugs in a universal healthcare setting (2020) (7)
Anxiety and depression affect performance on the symbol digit modalities test over time in MS and other immune disorders (2020) (7)
Obesity and HLA in multiple sclerosis (2014) (7)
Disparities in management and outcomes of myocardial infarction in multiple sclerosis: A matched cohort study (2019) (7)
Interrogation of the Multiple Sclerosis Prodrome Using High-Dimensional Health Data (2020) (7)
Prioritizing progressive MS rehabilitation research: A call from the International Progressive MS Alliance (2021) (7)
Relapses in multiple sclerosis (2009) (6)
Uptake of influenza vaccination among persons with inflammatory bowel disease, multiple sclerosis or rheumatoid arthritis: a population-based matched cohort study (2021) (6)
Risk of Mortality in Immigrants with Multiple Sclerosis in Ontario, Canada (2020) (6)
Patient Recruitment by Neurological Registries (2013) (6)
No Evidence for Impairment of Venous Hemodynamics in Children or Young Adults with Pediatric-Onset Multiple Sclerosis (2013) (6)
Use of the new oral disease-modifying therapies for multiple sclerosis in British Columbia, Canada: the first five-years. (2018) (6)
Effect of mood and anxiety disorders on health care utilization in multiple sclerosis (2020) (6)
Identifying optic neuritis and transverse myelitis using administrative data. (2018) (6)
Validation of an algorithm to detect severe MS relapses in administrative health databases. (2018) (6)
Pseudobulbar affect: Prevalence and association with symptoms in multiple sclerosis (2018) (6)
Interface of Multiple Sclerosis, Depression, Vascular Disease, and Mortality (2021) (6)
Functional gastrointestinal disorders negatively affect health-related quality of life in MS. (2019) (6)
Characteristics associated with drug-induced liver injury from interferon beta in multiple sclerosis patients (2014) (6)
Increased mental health care use by mothers of children with multiple sclerosis (2020) (6)
Effects of Vascular Comorbidity on Cognition in Multiple Sclerosis Are Partially Mediated by Changes in Brain Structure (2022) (6)
Incidence of Adverse Psychiatric Events During Treatment of Inflammatory Bowel Disease With Biologic Therapies: A Systematic Review (2019) (6)
Accuracy of Administrative Hospital Data to Identify Use of Life Support Modalities. A Canadian Study. (2020) (6)
Uptake and Attitudes About Immunizations in People With Multiple Sclerosis (2021) (5)
Social phobia in immune-mediated inflammatory diseases. (2019) (5)
Predictors of hospitalization in a Canadian MS population: A matched cohort study. (2020) (5)
Preventing multiple sclerosis (2017) (5)
Early neuroaxonal injury is seen in the acute phase of pediatric optic neuritis. (2019) (5)
Support for a non-therapist assisted, Internet-based cognitive-behavioral therapy (iCBT) intervention for mental health in rheumatoid arthritis patients (2021) (5)
Impact of Psychiatric Comorbidity on Health Care Use in Rheumatoid Arthritis: A Population‐Based Study (2020) (5)
Psychiatric comorbidity in multiple sclerosis: It’s not the genes (2014) (5)
A gestational dose of vitamin D per day keeps the MS doctor away (2017) (5)
The Impact of Psychiatric Comorbidity on Health Care Utilization in Inflammatory Bowel Disease: A Population-based Study. (2020) (5)
Predictors of Fear of Sexual Rejection in Individuals with Multiple Sclerosis (2015) (5)
Gender identity and sexual orientation affect health care satisfaction, but not utilization, in persons with Multiple Sclerosis. (2020) (5)
You get what you measure (2008) (5)
Mendelian randomization provides no evidence for a causal role in the bidirectional relationship between depression and multiple sclerosis (2021) (5)
Higher Framingham Risk Scores are associated with greater loss of brain volume over time in multiple sclerosis. (2021) (5)
What is the risk of suicide in multiple sclerosis? (2017) (5)
Comparative responsiveness of the health utilities index and the RAND-12 for multiple sclerosis (2021) (4)
Observational studies of treatment effectiveness: useful, useless or somewhere in between? (2013) (4)
Adherence to laboratory monitoring among people taking oral drugs for multiple sclerosis: A Canadian population-based study (2020) (4)
Predictors of ICU Admission and Outcomes 1 Year Post-Admission in Persons with IBD: A Population-based Study (2015) (4)
Disease-modifying therapy in multiple sclerosis: Two guidelines (almost) passing in the night (2018) (4)
Developing a crosswalk between the RAND-12 and the health utilities index for multiple sclerosis (2019) (4)
Mounting evidence for a multiple sclerosis prodrome (2019) (4)
Women's Health in Multiple Sclerosis: A Scoping Review (2022) (4)
Models of Care in Multiple Sclerosis: A Survey of Canadian Health Providers (2022) (4)
Serum neurofilament light chain in relapsing-remitting MS (2017) (4)
From the prodromal stage of multiple sclerosis to disease prevention (2022) (4)
Effect of comorbid mood and anxiety disorders on breast and cervical cancer screening in immune-mediated inflammatory disease. (2021) (4)
Psychiatric comorbidity in immune‐mediated inflammatory diseases (2021) (4)
Factors associated with health care utilization in pediatric multiple sclerosis. (2019) (4)
Serum MOG-IgG in children meeting multiple sclerosis diagnostic criteria (2022) (4)
Association between disease-modifying therapies for multiple sclerosis and healthcare utilisation on a population level: a retrospective cohort study (2019) (4)
The 5-Year Incidence of Mental Disorders in a Population-Based ICU Survivor Cohort. (2020) (3)
Multiple sclerosis in First Nations Canadians: A pilot comparison study (2016) (3)
Colorectal Cancer Survival in Multiple Sclerosis (2021) (3)
Markedly increased incidence of critical illness in adults with Type 1 diabetes (2017) (3)
Effect of adherence to the first-generation injectable immunomodulatory drugs on disability accumulation in multiple sclerosis: a longitudinal cohort study (2017) (3)
Lower prevalence of multiple sclerosis in First Nations Canadians (2018) (3)
Metagenomic Analysis of the Pediatric-Onset Multiple Sclerosis Gut Microbiome (2021) (3)
Physical activity and dentate gyrus volume in pediatric acquired demyelinating syndromes (2018) (3)
Health service utilization in immigrants with multiple sclerosis (2020) (3)
The association between childhood maltreatment and pain catastrophizing in individuals with immune-mediated inflammatory diseases. (2021) (3)
Higher health care use before a clinically isolated syndrome with or without subsequent MS. (2019) (3)
Feasibility of Using a Nationally Representative Telephone Survey to Monitor Multiple Sclerosis Prevalence in the United States (2020) (3)
Multiple Sclerosis and the Cancer Diagnosis (2022) (3)
New applications for independent activities of daily living in measuring disability in multiple sclerosis (2020) (3)
Pro-inflammatory adiponectin in pediatric-onset multiple sclerosis (2021) (3)
Disease-Modifying Therapies and Adherence in Multiple Sclerosis: Comparing Patient Self-Report with Pharmacy Records (2017) (3)
MRI utilization during the diagnostic and post-diagnostic phases in multiple sclerosis. (2019) (3)
Incidence and temporal trends of co-occurring personality disorder diagnoses in immune-mediated inflammatory diseases (2020) (3)
Pathways to cures for multiple sclerosis: A research roadmap (2022) (3)
The metabolic potential of the paediatric-onset multiple sclerosis gut microbiome. (2022) (3)
Charting a global research strategy for progressive MS—An international progressive MS Alliance proposal (2021) (3)
Development and Internal Validation of a Disability Algorithm for Multiple Sclerosis in Administrative Data (2021) (3)
Childhood Maltreatment and Psychiatric Comorbidity in Immune-Mediated Inflammatory Disorders (2021) (3)
Neurological Registry Feasibility and Sustainability (2013) (3)
Physical and Mental Health–Related Quality of Life Trajectories Among People With Multiple Sclerosis (2022) (2)
The health-related quality of life of children with multiple sclerosis is mediated by the health-related quality of life of their parents (2022) (2)
Adjusting for differential misclassification in matched case‐control studies utilizing health administrative data (2019) (2)
Cognitive test results in pediatric MS (2010) (2)
Depressive symptom trajectories and polygenic risk scores in individuals with an immune-mediated inflammatory disease (2022) (2)
Predictors of chronic cerebrospinal venous insufficiency procedure use among older people with multiple sclerosis: a national case–control study (2015) (2)
Attitudes toward coronavirus disease 2019 vaccination in people with multiple sclerosis (2022) (2)
Harnessing real-world data to inform treatment decisions in multiple sclerosis (2019) (2)
Disease-modifying therapies as cognition-modifying therapies? Treating cognitive impairment in MS (2020) (2)
Risk of infection-related hospitalizations in people with primary-progressive relative to relapsing-onset multiple sclerosis (P3.353) (2016) (2)
Disease-modifying drugs for multiple sclerosis and subsequent health service use (2021) (2)
Use of Benzodiazepines and Z-Drugs in Multiple Sclerosis (2022) (2)
Prevalence of Psychiatric Disorders is Increased Five Years before the Diagnosis in IBD (2017) (2)
A propensity-matched comparison of long-term disability worsening in patients with multiple sclerosis treated with dimethyl fumarate or fingolimod (2021) (2)
Development and internal validation of a multimorbidity index that predicts healthcare utilisation using the Canadian Longitudinal Study on Aging (2020) (2)
High prevalence of comorbidities at diagnosis in immigrants with multiple sclerosis (2021) (2)
Examining cognitive speed and accuracy dysfunction in youth and young adults with pediatric-onset multiple sclerosis using a computerized neurocognitive battery. (2021) (2)
Increased relapse rate during pregnancy and postpartum in neuromyelitis optica (2017) (2)
Disparities in Telehealth Care in Multiple Sclerosis (2022) (2)
Validation of Administrative Case Definitions for Diabetes, Hypertension and Hyperlipidemia in Persons with MS and Their Application To Determine Temporal Trends in Prevalence (P06.164) (2012) (2)
The Standards of Reporting of Neurological Disorders (STROND) checklist: Application to multiple sclerosis (2017) (2)
Application of pharmacogenomics to investigate adverse drug reactions to the disease-modifying treatments for multiple sclerosis: a case–control study protocol for dimethyl fumarate-induced lymphopenia (2017) (2)
Characterizing Long-term Disability Progression and Employment in NARCOMS Registry Participants with Multiple Sclerosis Taking Dimethyl Fumarate. (2021) (2)
Identifying people with multiple sclerosis in the Canadian Primary Care Sentinel Surveillance Network (2019) (2)
Health care utilisation before and after intensive care unit admission in rheumatoid arthritis. (2017) (2)
Maternal and fetal risks of natalizumab exposure in utero (2018) (2)
Interaction of HLA-DRB1*1501 and TNF-Alpha in a Population-based Case-control Study of Multiple Sclerosis. (2013) (2)
Interferons in secondary progressive multiple sclerosis (2007) (2)
Multiple Sclerosis and the Cancer Diagnosis: Diagnostic Route, Cancer Stage, and the Diagnostic Interval in Breast and Colorectal Cancer. (2022) (1)
Pharmaceutical cannabinoid use in Manitoba, 2004/05 to 2014/15: a population-based cross-sectional study. (2018) (1)
Prescription opioid use in multiple sclerosis (2022) (1)
Genome-wide scan identifies association between an interferon regulatory factor-related variant and interferon-beta induced liver injury in multiple sclerosis patients (2016) (1)
Sources of Cannabis Information and Medical Guidance for Neurologic Use (2022) (1)
Administrative data for observational research in multiple sclerosis: Opportunities and challenges (2021) (1)
Declines in the diagnosis of primary progressive MS: A critical change in phenotype or critical measurement error? (2016) (1)
Administrative databases for observational studies in multiple sclerosis: power or peril? (2014) (1)
Increased Incidence of Critical Illness in Psoriasis (2017) (1)
Multiple sclerosis and risk-taking. (2006) (1)
Mesenchymal stem cell therapy and cognition in MS: Preliminary findings from a phase II clinical trial. (2022) (1)
Variation in Time to First Disease Modifying Therapy in people with MS in the United States, United Kingdom, and Germany (517) (2020) (1)
Comorbidity and persistence of disease-modifying therapy use in relapsing remitting multiple sclerosis. (2021) (1)
Ten-year trajectories of health care utilization by Manitobans with MS predict nursing home entry (2018) (1)
Differences in Bladder Care for Veterans with Multiple Sclerosis by Treatment Location (2009) (1)
Incidence of neurological and psychiatric comorbidity over time: a population-based cohort study in Ontario, Canada. (2022) (1)
The Canadian prospective cohort study to understand progression in multiple sclerosis (CanProCo): rationale, aims, and study design (2021) (1)
Short-term laboratory and related safety outcomes for the multiple sclerosis oral disease-modifying therapies: an observational study (2020) (1)
Development of an indicator of smoking status for people with multiple sclerosis in administrative data (2022) (1)
Disease-Modifying Drugs for Multiple Sclerosis and Association With Survival (2022) (1)
Physical Comorbidities Are Associated with an Increased Risk of Psychiatric Comorbidity in Multiple Sclerosis (S37.004) (2016) (1)
Risk of Multiple Sclerosis Among Users of Antitumor Necrosis Factor α in 4 Canadian Provinces (2022) (1)
Author response: Comorbid anxiety, depression, and cognition in MS and other immune-mediated disorders (2019) (1)
Online Neurological Registries (2013) (1)
Appraisal of the multiple sclerosis functional composite (2003) (1)
Prevalence and Risk Factors of Substance Use Disorder in Rheumatoid Arthritis (2021) (1)
COMORBIDITY IN NEURODEGENERATIVE DISEASES AND MENTAL HEALTH CONDITIONS: IMPLICATIONS FOR HEALTH SYSTEM BURDEN (2019) (1)
A Survey of Cannabis Use in a Large US-Based Cohort of People with Multiple Sclerosis. (2021) (1)
Poster 230: Hand Function, Mobility, and Employment Status in the NARCOMS Registry (2010) (1)
Validating the diagnosis of multiple sclerosis using Swedish administrative data in Värmland County (2021) (1)
Marijuana Usage and Disability in MS in the NARCOMS Registry (P1.140) (2015) (1)
Factors Associated With Social Participation in Persons Living With Inflammatory Bowel Disease (2021) (1)
Does age at diagnosis influence the use of health services for multiple sclerosis? (2020) (1)
A New Computed Tool Detects Subtle Differences in Information Processing Speed in Children with Multiple Sclerosis (2014) (0)
Retinal Nerve Fiber Layer (RNFL) and Ganglion Cell Inner Plexiform Layer (GCIPL) in Persistently Myelin Oligodendrocyte Glycoprotein Antibody Positive Youth (P3.330) (2018) (0)
Validation of administrative case definitions for comorbid conditions in multiple sclerosis (2013) (0)
T-cell antigens in pediatric-onset multiple sclerosis: A unique window into early disease mechanisms (2017) (0)
Development Of Silent Brain Lesions In Pediatric Patients With Antibodies To Myelin Oligodendrocyte Glycoprotein (2020) (0)
Author response: High hypothetical interest in physician-assisted death in multiple sclerosis (2017) (0)
Factors Contributing to Nursing Home Entry Among People With Multiple Sclerosis (2016) (0)
Contents Vol. 48, 2017 (2017) (0)
Functional Gastrointestinal Disorders Negatively Affect Health-Related Quality of Life in Multiple Sclerosis (2019) (0)
Sa579 FACTORS ASSOCIATED WITH SOCIAL PARTICIPATION IN PERSONS LIVING WITH IBD (2021) (0)
Sa550 A POPULATION BASED ASSESSMENT OF THE COMORBID DISEASES OF THE CHARLSON COMORBIDITY INDEX IN IBD (2021) (0)
Contesting Medical Miracles: A Collective Action Framing Analysis of CCSVI and Venous Angioplasty (“Liberation Therapy”) for People With Multiple Sclerosis in News and Social Media (2018) (0)
1016 THE PREVALENCE OF OVERACTIVE BLADDER SYMPTOMS IN PATIENTS WITH MULTIPLE SCLEROSIS AND CORRELATIONS WITH INCREASED DISABILITY AS WELL AS REDUCED QUALITY OF LIFE (2010) (0)
Good multiple sclerosis (MS) care and how to get there in Canada: Perspectives of Canadian healthcare providers working with persons with MS (2023) (0)
Associations between courses of posttraumatic stress disorder and physical health conditions among Canadian military personnel. (2022) (0)
Characteristics of Switchers to Newer Therapies in the NARCOMS Registry (P3.282) (2015) (0)
Chronic Cerebrospinal Venous Insufficiency and Multiple Sclerosis: Changes in Treatment Patterns and Opinions in a Province-Wide Study (P05.183) (2013) (0)
Changes in Neurologic Disability and Health-Related Quality of Life Utility Over 8 Years in Patients with Multiple Sclerosis (P1.389) (2016) (0)
Adverse Impact of Comorbidity on Mortality in Multiple Sclerosis (P1.115) (2015) (0)
Common variation near IRF6 is associated with IFN-β-induced liver injury in multiple sclerosis (2018) (0)
Management of vascular risk in people with multiple sclerosis at the time of diagnosis in England: A population-based study. (2023) (0)
Breast Cancer Survival in Multiple Sclerosis (2021) (0)
Progressive retinal changes in pediatric multiple sclerosis. (2022) (0)
Genome-wide Scan Identifies Association Between an Interferon Regulatory Factor Variant and Interferon-beta Induced Liver Injury in Multiple Sclerosis Patients (2017) (0)
Stability of the gut microbiota in persons with paediatric-onset multiple sclerosis and related demyelinating diseases (2022) (0)
The Barancik lecture: Comorbidity in multiple sclerosis-Looking backward, looking forward. (2023) (0)
Addressing Health-Related Quality of Life Among Children With Multiple Sclerosis. (2023) (0)
CJN volume 40 issue S2 Cover and Front matter (2013) (0)
2010 McDonald Criteria for Diagnosing Pediatric Multiple Sclerosis (P01.155) (2012) (0)
Administrative Data Is Insufficient to Identify Near-Future Critical Illness: A Population-Based Retrospective Cohort Study (2022) (0)
Author's response to Dr. Masdeu (2018) (0)
1507 THE PREVELANCE OF URINARY CATHTERIZATION IN WOMEN AND MEN WITH MULTIPLE SCLEROSIS (2011) (0)
Systematic review of interventions for depression and anxiety in persons with inflammatory bowel disease (2016) (0)
Temporal Changes in Multiple Sclerosis onset age: Importance of Controlling for Equal Observation Time (2017) (0)
Recognizing the diversity gap in multiple sclerosis (2019) (0)
Low socioeconomic status was associated with a higher mortality risk in multiple sclerosis (2022) (0)
Anxiety and Diabetes Adversely Affect Cognition in Multiple Sclerosis (P1.423) (2018) (0)
Corrigendum to "Does Age at Diagnosis Influence the Use of Health Services for Multiple Sclerosis?" [Multiple Sclerosis and Related Disorders 46 (2020), 102555]. (2021) (0)
Sex and age differences in the Multiple Sclerosis prodrome (2022) (0)
How common is concurrent neurological and mood/anxiety disorder comorbidity over time? A population‐based cohort study in Ontario, Canada (2021) (0)
T36UNDERSTANDING PSYCHIATRIC COMORBIDITY IN CHRONIC IMMUNOINFLAMMATORY DISEASES USING GENOMICS (2019) (0)
Adverse early life events are not associated with pediatric multiple sclerosis (MS) (P3.217) (2017) (0)
Severity and worsening of fatigue among individuals with multiple sclerosis (2023) (0)
Psychometric Performance of Fatigue Scales in Inflammatory Bowel Disease. (2023) (0)
1017 THE PREVALENCE OF CATHETER UTILIZATION IN PATIENTS WITH MULTIPLE SCLEROSIS AND THE IMPACT ON QUALITY OF LIFE (2010) (0)
Phenotypic and Functional Analysis of Immune Cell Subsets in Pediatric-onset Multiple Sclerosis (MS): Towards Definition of Earliest Disease Mechanisms (P2.236) (2014) (0)
Hypoglycaemia and the risk of dementia: a population-based cohort study using exposure density sampling. (2022) (0)
Associations of Mid- and Late-Life Severe Hypoglycemic Episodes With Incident Dementia Among Patients With Type 2 Diabetes: A Population-Based Cohort Study. (2022) (0)
Depressive symptom trajectories in older adults with dementia and associated risk of functional decline (2015) (0)
Who Participates in MS Clinical Trials? The NARCOMS Experience (P3.044) (2016) (0)
Mo1902 – Mood and Anxiety Disorders and Persistance with Anti-TNF Therapy in Ibd (2019) (0)
A Population-Based Study Comparing Multiple Sclerosis Clinic Users and Non-Users in British Columbia, Canada (P3.354) (2016) (0)
Lael Anne Stone, MD (1959–2019) (2019) (0)
Characteristics of Poor Adherence to the Injectable Disease-Modifying Therapies in Multiple Sclerosis: A Cross-Canada Prospective Study (P2.067) (2016) (0)
AUTHORS RESPOND: Differing trends in the incidence of vascular comorbidity in MS and the general population (2018) (0)
Attitudes of people with multiple sclerosis toward brain donation (2023) (0)
MS in immigrants to Canada in the McDonald era: Increasing prevalence and risk factors (S44.001) (2018) (0)
Génie Biomédical COMPARISON OF MULTI-ECHO GRADIENT AND SPIN ECHO ( GRASE ) AND FAST SPIN ECHO ( FSE ) MRI SEQUENCES FOR T 1 W / T 2 W RATIO MAPPING (2017) (0)
Comparing the MSIS-29 and the Health Utilities Index Mark III in Multiple Sclerosis (2021) (0)
MSJ910500_supplemental_table_2 – Supplemental material for Adherence to laboratory monitoring among people taking oral drugs for multiple sclerosis: A Canadian population-based study (2020) (0)
Do Patterns of Early Disease Severity Predict Grade 12 Academic Achievement in Youths with Childhood-onset Chronic Rheumatic Diseases? (2023) (0)
Authors’ reply to Dr. Golan (2020) (0)
MRI Features Distinguish Monophasic ADEM from MS: Findings from a Canadian Cohort of Children with Incident CNS Demyelination (S50.002) (2012) (0)
Family health conditions and parental occupational status modify the relationship between pediatric-onset multiple sclerosis and parental health-related quality of life (2023) (0)
Prospective clinical and MRI characterization of children with serum anti-MOG antibodies meeting the multiple sclerosis diagnostic criteria (2018) (0)
Variation in Employment Status among People with MS in the United States, United Kingdom and Germany (P4.2-057) (2019) (0)
Emergency department use by persons with MS: A population-based descriptive study with a focus on infection-related visits (2022) (0)
Substantial Declines in Rates of Hospitalization in Multiple Sclerosis: A Population-Based Study (P4.151) (2014) (0)
A population-based study comparing multiple sclerosis clinic users and non-users in British Columbia, Canada (2017) (0)
Increased Risk of Intensive Care Unit Admission in Multiple Sclerosis (P03.205) (2013) (0)
Comparison of Multi-echo Gradient and Spin Echo (GRASE) and Fast Spin Echo (FSE) MRI Sequences for T1w/T2w Ratio Mapping (2017) (0)
The International Incidence and Prevalence of Neurological Diseases – Do We Really Know How Common Neurological Conditions Are? Challenges in Interpreting International Epidemiological Studies (P04.235) (2013) (0)
Association of Vitamin D Polygenic Risk Scores and Disease Outcome in People With Multiple Sclerosis (2022) (0)
Obesity and brain volume loss in multiple sclerosis (2018) (0)
Proteogenomic immune signatures delineate the landscape of pediatric acquired demyelinating syndromes (2022) (0)
POS1210 SAFETY AND IMMUNOGENICITY OF COVID-19 VACCINES IN PATIENTS WITH IMMUNE MEDIATED INFLAMMATORY DISEASE (2022) (0)
Abnormal responses of CD8+CD161high mucosal associated invariant T (MAIT) cells and CCR2+CCR5+ CD4 T cells contribute to disrupted balance of effector and regulatory T cells in pediatric-onset MS (2014) (0)
Comorbidity is Associated with Increased Pain and Fatigue in Multiple Sclerosis (P1.114) (2015) (0)
Predictors of Fear of Sexual Rejection in Individuals with Multiple Sclerosis (2014) (0)
Disease-Modifying Drug Uptake and Health Service Use in the Ageing MS Population (2022) (0)
T55. POLYGENICITY OF COMORBID DEPRESSION IN MULTIPLE SCLEROSIS (2022) (0)
Magnetization transfer saturation reveals subclinical optic nerve injury in pediatric-onset multiple sclerosis (2022) (0)
Multiple Sclerosis Therapeutics: The epidemiology of multiple sclerosis (2011) (0)
26 SOCIAL DETERMINANTS OF OUTCOMES IN IBD (2020) (0)
The Clinical Impact of Acute Demyelination of the Central Nervous System in Children (2014) (0)
Estimating annual prevalence of depression and anxiety disorder in multiple sclerosis using administrative data (2017) (0)
Non-Oral Poster 30: The Impact Of Overactive Bladder Symptoms And Treatments On Quality Of Life Measures In Patients With Multiple Sclerosis (2010) (0)
Arthritis A Population-based Study of Intensive Care Unit Admissions in Rheumatoid (2015) (0)
Department of Clinical Health Psychology, Faculty of Medicine (2019) (0)
Estimating annual prevalence of depression and anxiety disorder in multiple sclerosis using administrative data (2017) (0)
A Population-based Study of Grade 12 Academic Performance in Adolescents With Childhood-onset Chronic Rheumatic Diseases (2021) (0)
24 PSYCHIATRIC COMORBIDITY IN IBD INCREASES HEALTH CARE UTILIZATION (2020) (0)
MOG-IgG1 antibodies in children. (2018) (0)
Reproductive Issues in Multiple Sclerosis: Parental MS and Child Outcomes (The Research Perspective) (2017) (0)
High Frequency and Adverse Impact of Vertigo and Dizziness in Multiple Sclerosis (P07.075) (2012) (0)
Disrupted cognitive development following pediatric acquired demyelinating syndromes: a longitudinal study (2021) (0)
Early Clinical and MRI Predictors of Time to Second Attack and Disability in Children with Acute Demyelinating Syndromes: Findings from a Prospective National Cohort Study (S54.007) (2014) (0)
A171 FACTORS OF SOCIAL PARTICIPATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE (2021) (0)
For peer review only The Canadian Survey of Health, Lifestyle and Aging with Multiple Sclerosis; Methodology and Initial Results (2014) (0)
Comparison of the accuracy of the 7-item HADS Depression subscale and 14-item total HADS for screening for major depression: A systematic review and individual participant data meta-analysis. (2023) (0)
Physical Activity and Sedentary Behavior Patterns Across Weekdays and Weekend Days in Youth With Multiple Sclerosis and Controls. (2021) (0)
Care of persons with MS in clinical practice: Management by majority. (2016) (0)
Pregnancy Outcomes and Disease Course in NMOSD and MOGAD in CANOPTICS (N2.002) (2023) (0)
The comorbidity and cognition in multiple sclerosis (CCOMS) neuroimaging protocol: Study rationale, MRI acquisition, and minimal image processing pipelines (2022) (0)
A national case–control study investigating demographic and environmental factors associated with NMOSD (2023) (0)
Neuropsychological and Structural Neuroimaging Outcomes in LGI1-Limbic Encephalitis: A Case Study (2022) (0)
Mo1840 – Incidence of Adverse Psychiatric Effects of Biologic Therapies Used in the Treatment of Inflammatory Bowel Disease: A Systematic Review (2019) (0)
Increased adiponectin levels in serum of early pediatric onset MS induce pro-inflammatory responses of both myeloid cells and T cells (2014) (0)
A comparative study of the gut microbiota in immune-mediated inflammatory diseases—does a common dysbiosis exist? (2018) (0)
Control charts for chronic disease surveillance: testing algorithm sensitivity to changes in data coding (2022) (0)
Use of Benzodiazepines and Z-Drugs in Inflammatory Bowel Disease (2022) (0)
Vascular comorbidity is associated with decreased cognitive functioning in inflammatory bowel disease (2023) (0)
Tu1167 Determining the Treated Prevalence of Anxiety and Depression Using Administrative Data for Patients With IBD (2014) (0)
The Association of Mid-life and Late-life Hypoglycemia With Dementia Among Patients With Type 2 Diabetes: A Population-based Cohort Study (2022) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Ruth Ann Marrie?

Ruth Ann Marrie is affiliated with the following schools:

McGill University
University of Manitoba
University of Saskatchewan

Ruth Ann Marrie's Academic­Influence.com Rankings

Ruth Ann Marrie's Degrees

Why Is Ruth Ann Marrie Influential?

Ruth Ann Marrie's Published Works

Published Works

What Schools Are Affiliated With Ruth Ann Marrie?

Ruth Ann Marrie's AcademicInfluence.com Rankings